James M Daly sold $5.4M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 15,470 shares at an average of $347.45, traded Feb 27, 2025, filed Feb 28, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.4M at market
- +20Share of holdings soldSold 89% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-009079, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2025 | MOption exercise Common Stock | +9,470 | $65.06 | $616k | 11,382 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 17,382 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -398 | $346.90 | $138k | 16,984 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -14,302 | $347.39 | $5.0M | 2,682 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -770 | $348.94 | $269k | 1,912 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -9,470 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 50Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.2M 7,279 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.0M 7,616 shares | -6% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $25M 68,618 shares | +36% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $37M 97,065 shares | +50% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $480k 1,304 shares | -12% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $3.7M 10,000 shares | -79% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $17M 46,808 shares | -25% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $48M 129,172 shares | -41% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $17M 46,463 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.